Neuroprotection in Neonatal Encephalopathy
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Systems Neuroscience".
Deadline for manuscript submissions: closed (5 June 2020) | Viewed by 474
Special Issue Editors
2. Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA 6009, Australia
3. Department of Neurosurgery, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
Interests: neuroprotection; stroke; hypoxic-ischaemic encephalopathy; traumatic brain injury; in vitro neuronal cell injury models
Special Issues, Collections and Topics in MDPI journals
2. Centre for Neuromuscular and Neurological Disorders, the University of Western Australia, Nedlands, WA 6009, Australia
3. Department of Neurosurgery, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
Interests: Hypoxic-ischaemic encephalopathy; Encephalopathy of prematurity; Neonatal encephalopathy; Neuroprotection
Special Issue Information
Dear Colleagues,
Neonatal encephalopathy is a complex “umbrella” syndrome characterized by abnormal neurological function affecting preterm and term infants before, during or after the birth period. Neonatal encephalopathy can result from one or more conditions associated with hypoxic–ischemic encephalopathy (HIE), maternal factors (e.g., preeclampsia, maternal hypertension), genetic predispositions (e.g., deletions, mutations, polymorphisms), in utero infections, placental disorders (e.g., chorioamnionitis, funisitis), and metabolic abnormalities (e.g., pyruvate dehydrogenase deficiency, carnitine cycle defects) and is the leading cause of death and disability in the pediatric population. Moreover, in survivors, it may be the forerunner of devastating longer-term consequences such as cerebral palsy, epilepsy, and developmental delay. While hypothermia is currently the only available treatment for neonatal encephalopathy, it provides benefit in only ~20% of infants, and there are at present no other clinically effective pharmacological neuroprotective strategies that are capable of reducing the severity of brain injury. As a consequence, the development of effective and easy to administer neuroprotective agents or other strategies for infants with neonatal encephalopathy is an urgent priority.
Owing in part to the complex etiology of neonatal encephalopathy, many of the pathophysiological events associated with the syndrome have yet to be fully elucidated. Therefore, further research to investigate the pathophysiological cascades which follow the initial injury is required to provide a better understanding of its causes, identify new therapeutic targets, and, importantly, to aid in the development of novel or repurposed neuroprotective agents.
The aims of this Special Issue are to bring together cutting-edge research into neonatal encephalopathy, and to encourage the publication of novel experimental and clinical studies which advance our understanding of the underlying pathogenic processes, and the development of new therapeutic approaches.
Prof. Dr. Bruno Meloni
Dr. Adam B. Edwards
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hypoxic-ischaemic encephalopathy
- Encephalopathy of prematurity
- Neuroprotection
- Pathophysiology
